FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026775520> ?p ?o ?g. }

• W2026775520 endingPage "e12873" @default.
• W2026775520 startingPage "e12873" @default.
• W2026775520 abstract "Background We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C, given alone or as boost following a DNA plasmid vaccine expressing the same HIV-1 proteins plus Nef, in 114 healthy HIV-uninfected African adults. Methodology/Principal Findings Volunteers were randomized to 4 groups receiving the rAd5 vaccine intramuscularly at dosage levels of 1×1010 or 1×1011 particle units (PU) either alone or as boost following 3 injections of the DNA vaccine given at 4 mg/dose intramuscularly by needle-free injection using Biojector® 2000. Safety and immunogenicity were evaluated for 12 months. Both vaccines were well-tolerated. Overall, 62% and 86% of vaccine recipients in the rAd5 alone and DNA prime - rAd5 boost groups, respectively, responded to the HIV-1 proteins by an interferon-gamma (IFN-γ) ELISPOT. The frequency of immune responses was independent of rAd5 dosage levels. The highest frequency of responses after rAd5 alone was detected at 6 weeks; after DNA prime - rAd5 boost, at 6 months (end of study). At baseline, neutralizing antibodies against Ad5 were present in 81% of volunteers; the distribution was similar across the 4 groups. Pre-existing immunity to Ad5 did not appear to have a significant impact on reactogenicity or immune response rates to HIV antigens by IFN-γ ELISPOT. Binding antibodies against Env were detected in up to 100% recipients of DNA prime - rAd5 boost. One volunteer acquired HIV infection after the study ended, two years after receipt of rAd5 alone. Conclusions/Significance The HIV-1 rAd5 vaccine, either alone or as a boost following HIV-1 DNA vaccine, was well-tolerated and immunogenic in African adults. DNA priming increased the frequency and magnitude of cellular and humoral immune responses, but there was no effect of rAd5 dosage on immunogenicity endpoints. Trial Registration ClinicalTrials.gov NCT00124007" @default.
• W2026775520 created "2016-06-24" @default.
• W2026775520 creator A5004092087 @default.
• W2026775520 creator A5010176480 @default.
• W2026775520 creator A5015111622 @default.
• W2026775520 creator A5016028124 @default.
• W2026775520 creator A5016493721 @default.
• W2026775520 creator A5018876865 @default.
• W2026775520 creator A5020230187 @default.
• W2026775520 creator A5020665252 @default.
• W2026775520 creator A5021608465 @default.
• W2026775520 creator A5026529869 @default.
• W2026775520 creator A5027657945 @default.
• W2026775520 creator A5038738846 @default.
• W2026775520 creator A5038756960 @default.
• W2026775520 creator A5043775431 @default.
• W2026775520 creator A5045476784 @default.
• W2026775520 creator A5054509948 @default.
• W2026775520 creator A5056651704 @default.
• W2026775520 creator A5061211279 @default.
• W2026775520 creator A5067444034 @default.
• W2026775520 creator A5068604516 @default.
• W2026775520 creator A5069371766 @default.
• W2026775520 creator A5069835036 @default.
• W2026775520 creator A5073493145 @default.
• W2026775520 creator A5074469955 @default.
• W2026775520 creator A5076276906 @default.
• W2026775520 creator A5078709209 @default.
• W2026775520 creator A5082136599 @default.
• W2026775520 creator A5082827056 @default.
• W2026775520 creator A5083515370 @default.
• W2026775520 creator A5086450891 @default.
• W2026775520 creator A5089514918 @default.
• W2026775520 date "2010-09-21" @default.
• W2026775520 modified "2023-10-18" @default.
• W2026775520 title "Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa" @default.
• W2026775520 cites W1968487372 @default.
• W2026775520 cites W1970267929 @default.
• W2026775520 cites W2005346314 @default.
• W2026775520 cites W2010391664 @default.
• W2026775520 cites W2022158202 @default.
• W2026775520 cites W2028565545 @default.
• W2026775520 cites W2034160159 @default.
• W2026775520 cites W2046730970 @default.
• W2026775520 cites W2053035745 @default.
• W2026775520 cites W2081861662 @default.
• W2026775520 cites W2087337413 @default.
• W2026775520 cites W2104251050 @default.
• W2026775520 cites W2105323221 @default.
• W2026775520 cites W2105809563 @default.
• W2026775520 cites W2112887086 @default.
• W2026775520 cites W2116113310 @default.
• W2026775520 cites W2126666403 @default.
• W2026775520 cites W2138927891 @default.
• W2026775520 cites W2146108709 @default.
• W2026775520 cites W2152048324 @default.
• W2026775520 cites W2153670011 @default.
• W2026775520 cites W2155487723 @default.
• W2026775520 cites W2159369744 @default.
• W2026775520 cites W2160663355 @default.
• W2026775520 cites W2162891851 @default.
• W2026775520 cites W2163415145 @default.
• W2026775520 cites W2169962588 @default.
• W2026775520 cites W2171139716 @default.
• W2026775520 doi "https://doi.org/10.1371/journal.pone.0012873" @default.
• W2026775520 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2943475" @default.
• W2026775520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20877623" @default.
• W2026775520 hasPublicationYear "2010" @default.
• W2026775520 type Work @default.
• W2026775520 sameAs 2026775520 @default.
• W2026775520 citedByCount "91" @default.
• W2026775520 countsByYear W20267755202012 @default.
• W2026775520 countsByYear W20267755202013 @default.
• W2026775520 countsByYear W20267755202014 @default.
• W2026775520 countsByYear W20267755202015 @default.
• W2026775520 countsByYear W20267755202016 @default.
• W2026775520 countsByYear W20267755202017 @default.
• W2026775520 countsByYear W20267755202018 @default.
• W2026775520 countsByYear W20267755202019 @default.
• W2026775520 countsByYear W20267755202020 @default.
• W2026775520 countsByYear W20267755202021 @default.
• W2026775520 countsByYear W20267755202023 @default.
• W2026775520 crossrefType "journal-article" @default.
• W2026775520 hasAuthorship W2026775520A5004092087 @default.
• W2026775520 hasAuthorship W2026775520A5010176480 @default.
• W2026775520 hasAuthorship W2026775520A5015111622 @default.
• W2026775520 hasAuthorship W2026775520A5016028124 @default.
• W2026775520 hasAuthorship W2026775520A5016493721 @default.
• W2026775520 hasAuthorship W2026775520A5018876865 @default.
• W2026775520 hasAuthorship W2026775520A5020230187 @default.
• W2026775520 hasAuthorship W2026775520A5020665252 @default.
• W2026775520 hasAuthorship W2026775520A5021608465 @default.
• W2026775520 hasAuthorship W2026775520A5026529869 @default.
• W2026775520 hasAuthorship W2026775520A5027657945 @default.
• W2026775520 hasAuthorship W2026775520A5038738846 @default.
• W2026775520 hasAuthorship W2026775520A5038756960 @default.
• W2026775520 hasAuthorship W2026775520A5043775431 @default.
• W2026775520 hasAuthorship W2026775520A5045476784 @default.

• next